Overview
Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for the CDC-funded coordinating center of the influenza and other respiratory virus vaccine effectiveness network. This work provides national estimates for influenza and other respiratory virus vaccine effectiveness in persons presenting with respiratory illness in the ambulatory setting.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine effectiveness, vaccine coverage, prevention and treatment of infectious diseases.
Current Duke Appointments & Affiliations
Recent News Items
View All News Items
Recent Scholarly Works
Birth cohort effects in adults associated with influenza A(H1N1)pdm09 vaccine effectiveness.
Journal article J Infect Dis · June 8, 2026 BACKGROUND: In the 2023-24 influenza season, adults born in the 1957-1985 birth cohort had the lowest vaccine effectiveness (VE) against A(H1N1)pdm09 viruses than other age groups, including those in the 1986-2005 birth cohort. Here, we investigated A(H1N1 ... Full text Link to item CitePreventing Postvaccination Presyncope and Syncope in Adolescents: A Randomized Controlled Trial of a Clinic-Based Intervention.
Journal article J Pediatr · June 2026 OBJECTIVE: To study the impact of a combined intervention using Buzzy plus simultaneous distraction (playing video games on a tablet) on the incidence of postvaccination presyncope and syncope. STUDY DESIGN: We performed a randomized-controlled trial of a ... Full text Link to item CiteInfluenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season.
Journal article medRxiv · March 26, 2026 BACKGROUND: Influenza A(H1N1)pdm09 and A(H3N2) viruses predominated during the 2024-25 U.S. influenza season. We estimated influenza vaccine effectiveness (VE) in the United States against mild-to-moderate outpatient influenza illness by influenza type and ... Full text Link to item CiteRecent Grants
CIVICS Component C - Option 13B.1 Biorepository
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2026 - 2030Duke University Maternal-Fetal Medicine Units (MFMU) Network Clinical Center
ResearchCollaborating Investigator · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2023 - 2030CIVICS Component C - Option 16 EA - COBRA
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2029View All Grants